Identification of Tissue Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics

Purpose: Thyroid cancer is frequently difficult to diagnose due to an overlap of cytological features between malignant and benign nodules. This overlap leads to unnecessary removal of the thyroid in patients without cancer. While providing some improvement over cytopathologic diagnostics, molecular methods frequently fail to provide a correct diagnosis for thyroid nodules. These approaches are based on the difference between cancer and adjacent thyroid tissue and assume that adjacent tissues are the same as benign nodules. However, in contrast to adjacent tissues, benign thyroid nodules can contain genetic alterations that can be found in cancer. Experimental Design: For the development of a new molecular diagnostic test for thyroid cancer, we evaluated DNA methylation in 109 thyroid tissues by using genome wide single base resolution DNA methylation analysis. The test was validated in a retrospective cohort containing 65 thyroid nodules. Results: By conducting Reduced Representation Bisulfite Sequencing in 109 thyroid specimens, we found significant differences between adjacent tissue, benign nodules, and cancer. These tissue specific signatures are strongly linked to active enhancers and cancer associated genes. Based on these signatures, we developed a new epigenetic approach for thyroid diagnostics. According to the validation cohort, our test has an estimated specificity of 97% (95% CI, 81 to 100), sensitivity of 100% (95% CI, 87 to 100), PPV of 97% (95% CI, 83-100), and NPV of 100% (95% CI, 86 to 100). Conclusions: These data show that epigenetic testing can provide outstanding diagnostic accuracy for thyroid nodules.

https://ift.tt/2Ot1K2z